Meeting
2021 ASCO Annual Meeting
Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).
Authors
Kanwal Pratap Singh Raghav
The University of Texas MD Anderson Cancer Center, Houston, TX
Kanwal Pratap Singh Raghav , Yoshiaki Nakamura , Silvia Marsoni , John H. Strickler , Rona Yaeger , Aakash Tushar Shah , Wataru Okamoto , Giovanni Crisafulli , Rebecca Nagy , Victoria M. Raymond , Mark Routbort , Salvatore Siena , Ryan Bruce Corcoran , Alberto Bardelli , Scott Kopetz , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3589)
DOI
10.1200/JCO.2021.39.15_suppl.3589
Abstract #
3589
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for HER2-amplified biliary tract cancer.
First Author: Kanae Inoue
Poster
2023 ASCO Breakthrough
First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with HER2 amplification (HER2amp+), RAS wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.
First Author: Eiji Oki
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim
Poster
2023 ASCO Annual Meeting
Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
First Author: Giuseppe Di Caro